KK2845_3
Phase 1Small molecule
Kyowa Kirin Co., Ltd.KK2845_3 is one of 37 small molecule programs targeting Acute Myeloid Leukemia. It is currently in Phase 1.
2
Indications
1
Total Trials
1
Active Trials
36
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
804 competitors in Acute Myeloid Leukemia
#DrugCompanyPhaseTrials
1Decadron
AAspen Global Incorporated
Phase 3
Dalalone
CCSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Phase 3
Diflucan
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Caspofungin Acetate
Merck & Co.Phase 3
Experimental
BiogenPhase 3
Lenograstim
SanofiPhase 3
AG-120
Institut de Recherches Internationales ServierPhase 3
Valspodar
EEastern Cooperative Oncology Group
Phase 3
Salvage Chemotherapy
Daiichi SankyoPhase 3
Homoharringtonine
Ascentage Pharma Group Inc.Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for KK2845_3. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company